Thematics Asset Management Purchases 10,556 Shares of DexCom, Inc. (NASDAQ:DXCM)

Thematics Asset Management grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 256,729 shares of the medical device company's stock after acquiring an additional 10,556 shares during the period. Thematics Asset Management owned 0.07% of DexCom worth $19,966,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Versant Capital Management Inc purchased a new stake in DexCom during the 4th quarter worth about $25,000. Private Trust Co. NA lifted its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares in the last quarter. TD Private Client Wealth LLC boosted its position in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC boosted its position in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new position in DexCom during the fourth quarter valued at approximately $38,000. 97.75% of the stock is owned by institutional investors.

DexCom Trading Up 1.1 %

DXCM traded up $0.81 during midday trading on Friday, reaching $71.59. 1,374,473 shares of the company's stock traded hands, compared to its average volume of 4,231,208. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $139.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a fifty day moving average of $73.46 and a two-hundred day moving average of $76.61. The stock has a market capitalization of $28.07 billion, a price-to-earnings ratio of 50.11, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the subject of several analyst reports. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and upped their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley lifted their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Canaccord Genuity Group lifted their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $99.00.

Insider Buying and Selling

In other news, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company's stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,009 shares of company stock worth $8,044,178. 0.32% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.